Altered gut microbiota in patients with idiopathic Parkinson's disease: an age-sex matched case-control studyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether the gut microbiome is altered in idiopathic Parkinson's disease and whether changes relate to non-motor symptoms and disease duration. It used an age- and sex-matched case-control design. Microbial taxa in stool were profiled by 16S rRNA amplicon sequencing. Researchers compared taxa from phylum to genus level between patients and controls, and examined patients with and without non-motor symptoms.
Who was studied?
The cohort was 84 people from Turkey: 42 patients with idiopathic Parkinson's disease and 42 healthy spouses serving as matched controls. Using spouses helped control for shared environment and diet. Stool samples were collected from all 84 subjects for sequencing. The authors state this is the first gut microbiota study in Turkish Parkinson's patients and the first to examine microbiota effects on non-motor symptoms in this group.
What were the most important findings?
Patients showed a significant decrease in Firmicutes and a significant increase in Verrucomicrobiota at the phylum level. At the family level, Lactobacillaceae and Akkermansiaceae increased while Coriobacteriales Incertae Sedis decreased. At the genus level, only Lactobacillus increased significantly. Lachnospiraceae ND3007 group, Tyzzerella, Fusicatenibacter, Eubacterium hallii group, and Ruminococcus gauvreauii group all decreased. Prevotella decreased but not significantly. Microbiota composition also differed between patients with and without non-motor symptoms.
What are the greatest implications of this study?
The findings add to evidence that gut microbiota composition differs in Parkinson's disease, even against a matched-spouse baseline. Loss of several butyrate-associated genera fits a broader pattern reported in the disorder. The authors suggest disease duration influenced microbiota, which in turn related to non-motor symptoms, hinting at a gut-brain link. Because this is a cross-sectional case-control study, it shows associations rather than cause. The findings need confirmation in larger, longitudinal cohorts.